6:25 PM
 | 
Jan 23, 2013
 |  BC Extra  |  Clinical News

Celgene details Abraxane pancreatic cancer data

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III MPACT trial evaluating Abraxane nab-paclitaxel for metastatic pancreatic cancer and said it now plans to submit regulatory applications for the indication in the U.S. and EU this half. The company, which previously said it planned to submit an application in the U.S. sometime...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >